abstract |
Provided herein are novel antibodies that bind TGFßRII and methods of making and using such antibodies. The antibodies provided advantageously block TGFß activity in a broad population of cells (e.g., active and unactivated hematopoietic cells), and find use wherein such blockage of TGFß activity is desirable, for example, for the treatment of cancers. In some embodiments, the antibodies are novel αTGFßRII×αCD5 and αTGFßRII×αPD-1 bispecific antibodies. |